Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Enable Therapeutics
AddedFeb 18, 2024
UpdatedJun 18, 2026
Enable Therapeutics

Enable Therapeutics

Angel

Enable Therapeutics: A Massachusetts-based biotech firm innovating patented drug delivery platforms since 2020.

HQ
Hopedale, MA, US
Founded
2020
Overview
Compare
Fundraising
Employees

Enable Therapeutics is a biotechnology company developing a patented drug delivery platform.

The company was founded in 2020 and is headquartered in Hopedale, Massachusetts.

Enable Therapeutics - Similar Companies

Enable Medicine logo

Enable Medicine

enablemedicine.com

Enable Injections logo

Enable Injections

Enlaza Therapeutics logo

Enlaza Therapeutics

Extend Biosciences logo

Extend Biosciences

extendbio.com

Marlinspike Therapeutics logo

Marlinspike Therapeutics

SpringLeaf Therapeutics logo

SpringLeaf Therapeutics

Rekindle Therapeutics logo

Rekindle Therapeutics

Enavate Sciences logo

Enavate Sciences

Lattice Therapeutics logo

Lattice Therapeutics

Faze Medicines logo

Faze Medicines

fazemed.com

Enable Biosciences logo

Enable Biosciences

Mechano-Therapeutics logo

Mechano-Therapeutics

Ensem Therapeutics logo

Ensem Therapeutics

ensemtx.com

Enrich Therapeutics logo

Enrich Therapeutics

InSitu Biologics logo

InSitu Biologics

Enable Therapeutics - Quick Facts

Who are Enable Therapeutics' competitors?

Companies similar to Enable Therapeutics include Enable Medicine, Enable Injections, Enlaza Therapeutics and Extend Biosciences.

When was Enable Therapeutics founded?

Enable Therapeutics was founded in 2020.

Where is Enable Therapeutics' headquarters located?

Enable Therapeutics' headquarters is located in Hopedale, MA, US.

When was Enable Therapeutics' last funding round?

Enable Therapeutics' most recent funding round was for $251k (USD) in April 2021.

How much has Enable Therapeutics raised to-date?

As of Apr 20, 2021, Enable Therapeutics has raised a total of $251k (USD).

How many employees does Enable Therapeutics have?

Enable Therapeutics has 5 employees as of Feb 4, 2024.

Enable Therapeutics - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Model
  • Platform
Customer
  • Small Business
Main Product
  • Drug Delivery
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified